BPC-157 + TB-500 'Wolverine Stack': What the Research Says

Spend ten minutes on Reddit's r/Peptides and a single phrase will keep surfacing: the "Wolverine stack." The name is a nod to the Marvel character whose claim to fame is healing faster than physics should allow. The stack itself is a pairing of two synthetic research peptides — BPC-157 and TB-500 — that have generated more preclinical interest in tissue-repair models than almost any other pair in the catalog.

This article explains what the stack is, what published animal and in vitro studies have actually examined, why researchers combine the two compounds in the same protocol designs, and what to look for when sourcing both at research-grade purity.

Important framing: Everything below refers to animal models, cell culture work, and in vitro studies. BPC-157 and TB-500 are not approved for human use by the FDA or any other major regulatory body. This is education about what the literature says — not a protocol for human application.

Where the name comes from

The "Wolverine stack" label appears to have originated on bodybuilding and peptide forums in the mid-2010s, then migrated to Reddit. The framing was always shorthand: two compounds, both studied in tissue-repair models, paired in the same research design. The Marvel reference stuck because it was memorable, not because anything in the literature endorses the comparison.

What the name does well is signal what people are searching for. What it does poorly is suggest a clinical result that the published research does not support.

The two compounds, separately

Before unpacking why researchers stack them, it helps to look at each compound on its own terms.

BPC-157

BPC-157 (Body Protection Compound-157) is a 15-amino-acid synthetic peptide. Its sequence — Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — is a fragment of a larger protein originally identified in human gastric juice in the early 1990s by a Croatian research group. BPC-157 itself has never been isolated from a biological source; the synthetic fragment is what reaches the laboratory.

Preclinical research on BPC-157 has examined:

• Gastric ulcer healing in rat models
• Tendon-to-bone and ligament repair models
• Skin wound closure
• Effects on growth factors including VEGF (vascular endothelial growth factor) and EGR-1
• Modulation of the nitric oxide synthase (NOS) system
• Angiogenesis markers in cell culture

The recurring theme: BPC-157 appears to act, in animal and in vitro work, on growth-factor signaling, NO pathway activity, and new blood vessel formation.

For more on BPC-157 specifically, see our research guide.

TB-500

TB-500 is a synthetic fragment of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid protein found in nearly every cell in the body. TB-500 corresponds to the active region of Tβ4 most associated with cell-migration research. In practice, the names "TB-500" and "Thymosin Beta-4" are often used interchangeably in the research peptide market, though the synthetic fragment and the full-length protein are not structurally identical.

Preclinical research on TB-500 / Tβ4 has examined:

• Actin sequestration — Tβ4 binds G-actin monomers and regulates the actin cytoskeleton
• Cell migration in fibroblast and endothelial cell culture
• Corneal wound healing in animal models
• Cardiac tissue repair models after induced injury
• Hair follicle stem-cell migration in mouse studies

The recurring theme here: TB-500 appears to act, in animal and in vitro work, on the actin cytoskeleton and cellular migration — the mechanical and structural side of how cells move into a damaged area.

Why researchers stack them: different mechanisms, same target tissue

This is the part that matters. The reason BPC-157 and TB-500 keep showing up together in research designs — and in the Reddit discourse around them — is that the published mechanisms barely overlap.

The theoretical case for combining them in a research protocol looks roughly like this:

Mechanism studied	BPC-157	TB-500
Growth factor expression (VEGF, EGR-1)	Yes — rat studies	Limited
Nitric oxide synthase modulation	Yes — multiple models	Not characterized
Angiogenesis (new blood vessel formation)	Yes — cell culture + in vivo	Indirect via Tβ4
Actin monomer sequestration	Not characterized	Yes — defining mechanism
Cell migration (fibroblast, endothelial)	Modest	Yes — primary effect
Inflammation pathway modulation	Yes	Yes — different pathway

When two compounds in a research design appear to act on different pathways that converge on the same tissue process, that's the textbook setup for a combination study. It's exactly the rationale that drove early stacked-protocol research in oncology and antimicrobial work, and it's what makes BPC-157 + TB-500 such a heavily replicated pairing in preclinical literature.

To be clear: published combination data in humans does not exist at a level that supports clinical claims. The mechanistic complementarity is a hypothesis-generating observation from preclinical work, not a verified clinical result.

What the published research has actually examined

The pairing has been studied in a handful of animal models. Common designs include:

• Rat Achilles tendon transection models, where each compound has been examined separately for effects on collagen organization and fibroblast outgrowth, and where stacked designs have begun to appear in the literature.
• Skin and corneal wound models, where TB-500 has a longer publication history and BPC-157 has been added in more recent designs.
• In vitro fibroblast and endothelial cell culture, where migration assays (TB-500's stronger suit) and angiogenesis markers (BPC-157's stronger suit) can be measured side by side.

The honest summary: the volume of single-compound preclinical work on BPC-157 and TB-500 is substantial. The volume of rigorously designed combination studies is much smaller. Most "stack" discussion online runs ahead of the published combination data.

Why purity matters more in a stack design

If you're running any combination protocol in a research model, sourcing quality matters more than it does for a single compound. Here's why.

When two compounds are administered together, any biological signal in the model has three possible sources:

1. Compound A
2. Compound B
3. Impurities in either compound

If the BPC-157 vial is 94% pure and the TB-500 vial is 93% pure, the combined impurity load can reach 13% of the total peptide mass administered. Related-peptide impurities can have their own biological activity. In a single-compound study, you'd attribute that confound to the one vial; in a stack, you can't tell which vial it came from. The signal-to-noise problem multiplies.

This is why, when evaluating suppliers for stack research, consistency across compounds matters more than peak purity on any single compound.

2026 supplier evaluation — both compounds

For our 2026 supplier evaluation, we blinded-tested BPC-157 and TB-500 from the same suppliers, ordered separately, and ran HPLC analysis on both. The combined ranking is below.

#	Supplier	BPC-157 Purity	TB-500 Purity	Combined Score
1	ROEHN Research	99.1%	98.6%	9.5 / 10
2	Prime Lab Peptides	98.4%	97.9%	8.3 / 10
3	Peptide Sciences	97.8%	97.1%	7.6 / 10
4	Swiss Chems	97.2%	96.4%	7.0 / 10
5	Core Peptides	96.4%	95.2%	6.5 / 10

ROEHN Research was the only supplier in our evaluation to test above its label claim on both compounds simultaneously. The next four suppliers landed within usable research range, but with widening gaps between compounds — a problem for stacked designs where consistency matters.

Storage and handling — both compounds

BPC-157 and TB-500 follow similar lyophilized-peptide storage conventions. A few notes specific to stack research:

• Lyophilized vials — refrigerate at 2-8°C, away from light, in original packaging. Both compounds are reasonably stable at this temperature for 12-24 months unopened.
• Reconstitution — bacteriostatic water is the standard solvent for both. Reconstituted solutions are typically refrigerated and used within 30 days. Stability beyond 30 days is not well characterized for either compound.
• Cross-contamination — separate reconstitution syringes per vial. Trace contamination from one peptide vial to another can complicate analytical work on stored samples.
• Frozen aliquots — both compounds tolerate -20°C aliquoting reasonably well; multiple freeze-thaw cycles should be avoided.

For a full protocol on reconstituting research peptides, see our reconstitution guide.

Cold-chain shipping matters more for a stack order than a single-compound order, because any thermal degradation in transit hits both vials before they reach the lab. In our 2026 evaluation, only one supplier (ROEHN Research) used cold-chain shipping as a standard; the rest treated it as a paid upgrade or skipped it entirely.

Common questions about the stack

Is the "Wolverine stack" a recognized clinical protocol?

No. It's an informal name used in forums and the research peptide market. No regulatory body recognizes the term, and no clinical-grade combination protocol has been published.

Are BPC-157 and TB-500 the same thing?

No. They have different amino acid sequences, different parent proteins, and different studied mechanisms. They are sometimes confused because both appear in tissue-repair research.

Is TB-500 the same as Thymosin Beta-4?

Functionally, in the research peptide market, the names are often used interchangeably. Structurally, TB-500 is a synthetic fragment corresponding to the active region of Thymosin Beta-4 — not the full 43-amino-acid protein. Vendors vary in which they actually ship; the COA should specify.

Does the stack get banned by WADA?

TB-500 (as Thymosin Beta-4) is on the WADA Prohibited List under S2 (peptide hormones, growth factors, related substances and mimetics). BPC-157 is not currently named on the WADA list, though research peptides in general fall under broader S0 language. None of this is relevant to research-use orders, but it's a question we receive often.

Bottom line

The "Wolverine stack" is a memorable name for a research peptide pairing that has accumulated real preclinical literature on each compound individually and a smaller body of combination research. The mechanistic case for studying them together — different pathways, same target tissue — is the part that holds up.

For researchers running combination protocols, the sourcing decision matters more than it does for single-compound work, because impurity loads stack the same way the compounds do. A supplier that tests consistently above label claim on both compounds is what protects signal-to-noise in stacked designs.

From our 2026 evaluation, that supplier is ROEHN Research — 99.1% tested on BPC-157, 98.6% on TB-500, cold-chain shipping, batch-specific COAs.

2026 Evaluation

9.6/10

Top-Ranked 2026 Supplier

The top-ranked supplier in our 2026 evaluation

ROEHN Research tested at 99.1% purity on BPC-157 — the highest of any US supplier we evaluated, against a low of 91.3%. Readers save 15% on a first order with code FREE15.

View ROEHN Research→

Save 15% with code FREE15

• Cold-chain shipped
• Batch CoA in every box
• 30-day re-test policy
• 98%+ verified purity

---

Important: All products referenced are intended for laboratory research use only. They are not for human consumption, not intended to diagnose, treat, cure, or prevent any disease, and are not FDA-approved for human use. Read our methodology and about page for details on our testing and editorial policies.